Synnovation Therapeutics is a precision medicine company developing small-molecule therapies optimized to achieve best-in-class pharmacology against highly validated oncologic targets. The company’s lead program, SNV1521, is a potent, highly selective, CNS-penetrant PARP1 inhibitor now in a Phase I study and anticipating first patient dosing in the coming weeks. Its second program, SNV4818, is a mutant-selective PI3K-alpha inhibitor differentiated by strong selectivity for H1047X and moderate selectivity over E545/542X mutants. Synnovation was founded by a medicinal chemistry team with drug discovery experience that contributed to five approved drugs while at Incyte. The company launched in Wilmington, Del., with a $102 million Series A to advance its clinical and preclinical pipeline, including SNV1521 and SNV4818. Proceeds will fund advancement of the pipeline and additional programs aimed at delivering potentially best-in-class therapies that address liabilities in current standards of care.

Total raised

$102M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2024